美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Militia Long/Short Equity ETF

33.61

+0.51581.56%

盘后：33.46-0.1508-0.45%16:10 EST

成交量：2.86万

成交额：95.75万

市值：1.65亿

市盈率：- -

高：33.65

开：33.25

低：33.21

收：33.10

52周最高：34.00

52周最低：25.63

股本：492.00万

流通股本：453.00万

量比：0.21

换手率：0.63%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

君赛生物赴港IPO：核心产品数据平平且专利仍待审批递表前股东要求回购或转让股权

新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？

吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25

iza-bren食管鳞癌Ⅲ期临床期中分析迎关键突破

每日经济新闻

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ORR"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":33.6108,"timestamp":1766091600000,"preClose":33.095,"halted":0,"volume":28648,"hourTrading":{"tag":"盘后","latestPrice":33.46,"preClose":33.6108,"latestTime":"16:10 EST","volume":3,"amount":100.9816,"timestamp":1766092204575},"delay":0,"floatShares":4530000,"shares":4920000,"eps":0,"marketStatus":"未开盘","change":0.5158,"latestTime":"12-18 16:00:00 EST","open":33.25,"high":33.651,"low":33.21,"amount":957477.8782,"amplitude":0.013325,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":33.095,"sharesOutstanding":5000000,"nav":33.06,"aum":165300000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.46,"preClose":33.6108,"latestTime":"16:10 EST","volume":3,"amount":100.9816,"timestamp":1766092204575},"volumeRatio":0.206766},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":4530000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.206766,"shares":4920000,"dividePrice":0,"high":33.651,"amplitude":0.013325,"preClose":33.095,"low":33.21,"week52Low":25.63,"pbRate":"--","week52High":34,"institutionHeld":0,"latestPrice":33.6108,"eps":0,"divideRate":0,"volume":28648,"delay":0,"ttmEps":0,"open":33.25,"prevYearClose":25.88,"prevWeekClose":33.4384,"prevMonthClose":33.5975,"prevQuarterClose":31.475,"fiveDayClose":33.5884,"twentyDayClose":32.9,"sixtyDayClose":31.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592502964","title":"君赛生物赴港IPO：核心产品数据平平且专利仍待审批 递表前股东要求回购或转让股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2592502964","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592502964?lang=zh_cn&edition=fundamental","pubTime":"2025-12-17 15:10","pubTimestamp":1765955400,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　近日，上海君赛生物股份有限公司正式向港交所递交招股说明书。招股书显示，公司专注于实体瘤创新细胞疗法的生物科技公司，其核心产品GC101为全球首款无需高强度清淋化疗及IL-2给药的肿瘤浸润淋巴细胞疗法，承载着成为国内首个获批TIL疗法的期望。　　TIL细胞疗法是指通过离体激活来源于肿瘤组织内部的TIL细胞、规模扩增并注入患者体内发挥疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-12-17/doc-inhcavhm7560592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4107","BK4505","L","TIL","PFS","ORR","BK4588","LU0210528500.USD","LU2487616109.SGD","BK4211","BK4139","LU0053666078.USD","BK4585","BK4195"],"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590394122?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2065731478.USD","ORR","BK4187","BK4588","BK4585","LU0963586101.USD","BK4080","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","BK4107","BK4006","L","LU2487616109.SGD","BK4231","ADC","LU0210528500.USD","CRS","IE00B19Z4B17.USD","LU0053666078.USD"],"gpt_icon":0},{"id":"2590451393","title":"吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590451393?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 11:58","pubTimestamp":1765166299,"startTime":"0","endTime":"0","summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015952.SGD","LU0882574055.USD","BK4578","BK4109","BK4588","IE00B19Z4B17.USD","SG9999015978.USD","IE00B7SZLL34.SGD","LU0234570918.USD","IE00B3T34201.USD","BK4568","KOL","BK4585","BK4195","LU0289739699.SGD","BK4532","IE00B7SZL793.SGD","LU1778281490.HKD","OS","CR","CRS","SG9999015986.USD","ASH","BK4139","IE00BKVL7J92.USD","LU1430594728.SGD","LU1839511570.USD","IE0002270589.USD","LU1674673428.USD","SG9999015945.SGD","BK4550","BK4097","IE00B19Z3581.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","IE00B66KJ199.SGD","LU1066051498.USD","LU1585245621.USD","PFS","BK4187","IE00B19Z3B42.SGD","LU1674673691.USD","LU0823416689.USD","GILD","LU0320765992.SGD","BK4566","ORR","LU1571399168.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2584941686","title":"iza-bren食管鳞癌Ⅲ期临床期中分析迎关键突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2584941686","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584941686?lang=zh_cn&edition=fundamental","pubTime":"2025-11-19 21:09","pubTimestamp":1763557767,"startTime":"0","endTime":"0","summary":"在创新药研发的竞技场上，Ⅲ期临床的“期中大考”是检验药物价值的试金石。11月18日，百利天恒（SH688506，股价369.30元，市值1525.00亿元）宣布其核心产品——全球首创的EGFR×HER3双抗ADC（抗体药物偶联物）药物izabren，在晚期食管鳞癌Ⅲ期临床试验的预设期中分析中，同时达到无进展生存期和总生存期双主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511193569015549.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511193569015549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4097","91194","02615","BK4211","ORR","PFS","OS","BK4195"],"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}